Bei Ke Cai Jing·2025-10-26 08:48Core Viewpoint - WuXi AppTec announced the sale of 100% equity in two subsidiaries for a base price of 2.8 billion yuan, aligning with its strategy to focus on CRDMO business and enhance global capabilities [1] Group 1: Transaction Details - The transaction involves the transfer of equity in Shanghai Kande Hongyi Medical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. [1] - The buyers are newly established companies under Hillhouse Capital, which focuses on healthcare, manufacturing, green energy, hard technology, and consumer technology [1] Group 2: Strategic Implications - The sale is part of the company's strategy to concentrate on drug discovery, laboratory testing, and process development and production services [1] - The transaction is expected to provide financial support for accelerating the company's global capabilities and capacity deployment [1]